Case Comprehensive Cancer Center
case.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
489
Active
77
Phase 3
12
Total enrollment
33,685
Pipeline matrix
Showing 35 of 35 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Neoadjuvant chemotherapy | — | — | — | — | 2 | ||
| tacrolimus | — | — | — | 4 | |||
| oxaliplatin | — | — | — | — | 10 | ||
| CPX-351 | — | — | — | — | — | 2 | |
| Metronidazole | — | — | — | — | — | 1 | |
| Sitagliptin | — | — | — | — | — | 1 | |
| Trifluridine/tipiracil | — | — | — | — | — | 1 | |
| BCMA bispecific | — | — | — | — | — | 1 | |
| Pembrolizumab at 7 days prior | — | — | — | — | — | 1 | |
| Pembrolizumab at 14 days post | — | — | — | — | — | 1 | |
| Pembrolizumab at 35 days post | — | — | — | — | — | 1 | |
| Cabazitaxel and carboplatin | — | — | — | — | — | 1 | |
| Lu-PSMA-617 | — | — | — | — | — | 1 | |
| Androgen deprivation therapy | — | — | — | — | — | 1 | |
| Androgen receptor signaling inhibitor | — | — | — | — | — | 1 | |
| Adjuvant systemic therapy | — | — | — | — | — | 1 | |
| Haplo-Identical / Cord Blood Transplant | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 1 | |
| ALA | — | — | — | — | — | 1 | |
| Memantine | — | — | — | — | — | 1 | |
| Methimazole | — | — | — | — | — | 1 | |
| alemtuzumab | — | — | — | 4 | |||
| temozolomide | — | — | — | 6 | |||
| Standard-of-Care Immunotherapy | — | — | — | — | — | 1 | |
| Ivosidenib | — | — | — | — | — | 1 | |
| mFOLFIRINOX | — | — | — | — | — | 1 | |
| Ibrutinib | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Disulfiram | — | — | — | — | — | 1 | |
| Copper Gluconate | — | — | — | — | — | 1 | |
| Liposomal Doxorubicin | — | — | — | — | — | 1 | |
| Nicotinamide riboside | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 2 | |
| Novel probiotic | — | — | — | — | — | 1 | |
| WES via Illumina NextSeq 550 sequencing system | — | — | — | — | — | 1 |
Next readouts
- 2023-04-04
- 2024-03-20
- 2025-12
- 2026-01-19
- 2026-07-01
- 2026-07-15
- 2026-09
- 2026-09
- 2026-09-01
- 2026-10-01
Top conditions
- Breast Cancer56
- Prostate Cancer32
- Lymphoma27
- Unspecified Adult Solid Tumor, Protocol Specific27
- Lung Cancer24
- Leukemia21
- Myelodysplastic Syndromes19
- Head and Neck Cancer16
Frequently asked questions about Case Comprehensive Cancer Center
- How many clinical trials does Case Comprehensive Cancer Center have on ClinicalTrials.gov?
- Case Comprehensive Cancer Center is listed as the lead sponsor on 489 clinical trials in ClinicalTrials.gov, 77 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Case Comprehensive Cancer Center's trials are in Phase 3?
- 12 of Case Comprehensive Cancer Center's trials are in Phase 3, spread across 35 active drug programs.
- What therapeutic areas does Case Comprehensive Cancer Center focus on?
- Case Comprehensive Cancer Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Lung Cancer.
- When are Case Comprehensive Cancer Center's next clinical trial readouts?
- Case Comprehensive Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma”, expected around 2023-04-04.